Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4and resolvin E1

FASEB Journal

Volumn 25, Issue 5, 2011, Pages 1697-1705

  Wan, Min ^a   Godson, Catherine ^b   Guiry, Patrick J ^b   Agerberth, Birgitta ^a   Haeggström, Jesper Z ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cathelicidin; Eicosanoid; Inflammation; Resolution

Indexed keywords

BLT1 PROTEIN; CALCIUM; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CHEMERIN; CHEMR23 PROTEIN; CYTOSOLIC PHOSPHOLIPASE A2; FPR2 ALX PROTEIN; G PROTEIN COUPLED RECEPTOR; ICOSAPENTAENOIC ACID; LEUKOTRIENE B4; LIPOXIN A; MITOGEN ACTIVATED PROTEIN KINASE 14; PEPTIDE; PROTEIN DERIVATIVE; RECEPTOR PROTEIN; RESOLVIN E1 PROTEIN; UNCLASSIFIED DRUG; 5S,12R,18R TRIHYDROXY 6Z,8E,10E,14Z,16E EICOSAPENTAENOIC ACID; 5S,12R,18R-TRIHYDROXY-6Z,8E,10E,14Z,16E-EICOSAPENTAENOIC ACID; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE BINDING PROTEIN; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; DRUG DERIVATIVE; FORMYLPEPTIDE RECEPTOR; FPR2 PROTEIN, HUMAN; LEUKOTRIENE B4 RECEPTOR; LIPOXIN; LIPOXIN RECEPTOR; LTB4R PROTEIN, HUMAN; PHOSPHOLIPASE A2 GROUP IV;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; INFLAMMATION; NEUROPIL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; CELL CULTURE; DRUG EFFECT; ENZYME IMMUNOASSAY; METABOLISM; NEUTROPHIL; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING;

ANTIMICROBIAL CATIONIC PEPTIDES; BLOTTING, WESTERN; CALCIUM; CELLS, CULTURED; EICOSAPENTAENOIC ACID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GROUP IV PHOSPHOLIPASES A2; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKOTRIENE B4; LIPOXINS; NEUTROPHILS; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LEUKOTRIENE B4; RECEPTORS, LIPOXIN;

EID: 79955673539     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.10-175687     Document Type: Article

References (55)

1. Witko-Sarsat, V., Rieu, P., Descamps-Latscha, B., Lesavre, P., and Halbwachs-Mecarelli, L. (2000) Neutrophils: molecules, functions and pathophysiological aspects. Lab. Invest. 80, 617-653
2. De, Y., Chen, Q., Schmidt, A. P., Anderson, G. M., Wang, J. M., Wooters, J., Oppenheim, J. J., and Chertov, O. (2000) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192, 1069-1074
3. Agerberth, B., Charo, J., Werr, J., Olsson, B., Idali, F., Lindbom, L., Kiessling, R., Jornvall, H., Wigzell, H., and Gudmundsson, G. H. (2000) The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96, 3086-3093
4. Koczulla, R., von Degenfeld, G., Kupatt, C., Krotz, F., Zahler, S., Gloe, T., Issbrucker, K., Unterberger, P., Zaiou, M., Lebherz, C., Karl, A., Raake, P., Pfosser, A., Boekstegers, P., Welsch, U., Hiemstra, P. S., Vogelmeier, C., Gallo, R. L., Clauss, M., and Bals, R. (2003) An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 111, 1665-1672 (Pubitemid 38057748)
5. Nagaoka, I., Tamura, H., and Hirata, M. (2006) An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptorlike 1 and P2X7. J. Immunol. 176, 3044-3052
6. Elssner, A., Duncan, M., Gavrilin, M., and Wewers, M. D. (2004) A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J. Immunol. 172, 4987-4994
7. Tokumaru, S., Sayama, K., Shirakata, Y., Komatsuzawa, H., Ouhara, K., Hanakawa, Y., Yahata, Y., Dai, X., Tohyama, M., Nagai, H., Yang, L., Higashiyama, S., Yoshimura, A., Sugai, M., and Hashimoto, K. (2005) Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J. Immunol. 175, 4662-4668 (Pubitemid 41362007)
8. Tjabringa, G. S., Aarbiou, J., Ninaber, D. K., Drijfhout, J. W., Sorensen, O. E., Borregaard, N., Rabe, K. F., and Hiemstra, P. S. (2003) The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J. Immunol. 171, 6690-6696 (Pubitemid 37532101)
9. Zhang, Z., Cherryholmes, G., Chang, F., Rose, D. M., Schraufstatter, I., and Shively, J. E. (2009) Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils. Eur. J. Immunol. 39, 3181-3194
10. Mookherjee, N., Lippert, D. N., Hamill, P., Falsafi, R., Nijnik, A., Kindrachuk, J., Pistolic, J., Gardy, J., Miri, P., Naseer, M., Foster, L. J., and Hancock, R. E. (2009) Intracellular receptor for human host defense peptide LL-37 in monocytes. J. Immunol. 183, 2688-2696
11. Lin, L. L., Wartmann, M., Lin, A. Y., Knopf, J. L., Seth, A., and Davis, R. J. (1993) cPLA2 is phosphorylated and activated by MAP kinase. Cell 72, 269-278
12. Kramer, R. M., Roberts, E. F., Um, S. L., Borsch-Haubold, A. G., Watson, S. P., Fisher, M. J., and Jakubowski, J. A. (1996) p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J. Biol. Chem. 271, 27723-27729
13. Syrbu, S. I., Waterman, W. H., Molski, T. F., Nagarkatti, D., Hajjar, J. J., and Sha'afi, R. I. (1999) Phosphorylation of cytosolic phospholipase A2 and the release of arachidonic acid in human neutrophils. J. Immunol. 162, 2334-2340
14. Peters-Golden, M., and Henderson, W. R., Jr. (2007) Leukotrienes. N. Engl. J. Med. 357, 1841-1854
15. Brink, C., Dahlen, S. E., Drazen, J., Evans, J. F., Hay, D. W., Nicosia, S., Serhan, C. N., Shimizu, T., and Yokomizo, T. (2003) International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. 55, 195-227
16. Peters-Golden, M., Canetti, C., Mancuso, P., and Coffey, M. J. (2005) Leukotrienes: underappreciated mediators of innate immune responses. J. Immunol. 174, 589-594 (Pubitemid 40103563)
17. Wan, M., Sabirsh, A., Wetterholm, A., Agerberth, B., and Haeggstrom, J. Z. (2007) Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses. FASEB J. 21, 2897-2905
18. Chiang, N., Fierro, I. M., Gronert, K., and Serhan, C. N. (2000) Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J. Exp. Med. 191, 1197-1208
19. Chiang, N., Serhan, C. N., Dahlen, S. E., Drazen, J. M., Hay, D. W., Rovati, G. E., Shimizu, T., Yokomizo, T., and Brink, C. (2006) The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58, 463-487 (Pubitemid 44394909)
20. Fierro, I. M., Colgan, S. P., Bernasconi, G., Petasis, N. A., Clish, C. B., Arita, M., and Serhan, C. N. (2003) Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. J. Immunol. 170, 2688-2694
21. Maddox, J. F., and Serhan, C. N. (1996) Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J. Exp. Med. 183, 137-146
22. Godson, C., Mitchell, S., Harvey, K., Petasis, N. A., Hogg, N., and Brady, H. R. (2000) Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164, 1663-1667
23. Maderna, P., Cottell, D. C., Toivonen, T., Dufton, N., Dalli, J., Perretti, M., and Godson, C. (2010) FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J. 24, 4240-4249
24. Serhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., and Gronert, K. (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204
25. Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., Yang, R., Petasis, N. A., and Serhan, C. N. (2005) Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201, 713-722
26. Schwab, J. M., Chiang, N., Arita, M., and Serhan, C. N. (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447, 869-874
27. Hasturk, H., Kantarci, A., Ohira, T., Arita, M., Ebrahimi, N., Chiang, N., Petasis, N. A., Levy, B. D., Serhan, C. N., and Van Dyke, T. E. (2006) RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. FASEB J. 20, 401-403
28. Haworth, O., Cernadas, M., Yang, R., Serhan, C. N., and Levy, B. D. (2008) Resolvin E1 regulates interleukin 23, interferongamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat. Immunol. 9, 873-879
29. Arita, M., Ohira, T., Sun, Y. P., Elangovan, S., Chiang, N., and Serhan, C. N. (2007) Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. 178, 3912-3917
30. O'Sullivan, T. P., Vallin, K. S., Shah, S. T., Fakhry, J., Maderna, P., Scannell, M., Sampaio, A. L., Perretti, M., Godson, C., and Guiry, P. J. (2007) Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities. J. Med. Chem. 50, 5894-5902
31. Kennedy, C., and Leff, P. (1995) How should P2X purinoceptors be classified pharmacologically? Trends Pharmacol. Sci. 16, 168-174
32. Herbst, R. S. (2004) Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 59, 21-26
33. Murphy, P. M. (1994) The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12, 593-633
34. Scott, M. G., Davidson, D. J., Gold, M. R., Bowdish, D., and Hancock, R. E. (2002) The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J. Immunol. 169, 3883-3891
35. Nijnik, A., and Hancock, R. E. (2009) The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr. Opin. Hematol. 16, 41-47
36. Le, Y., Li, B., Gong, W., Shen, W., Hu, J., Dunlop, N. M., Oppenheim, J. J., and Wang, J. M. (2000) Novel pathophysiological role of classical chemotactic peptide receptors and their communications with chemokine receptors. Immunol. Rev. 177, 185-194
37. Lee, H. Y., Jo, S. H., Lee, C., Baek, S. H., and Bae, Y. S. (2006) Differential production of leukotriene B4 or prostaglandin E2 by WKYMVm or serum amyloid A via formyl peptide receptor-like 1. Biochem. Pharmacol. 72, 860-868 (Pubitemid 44301051)
38. Clish, C. B., O'Brien, J. A., Gronert, K., Stahl, G. L., Petasis, N. A., and Serhan, C. N. (1999) Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. U. S. A. 96, 8247-8252
39. Kenakin, T. (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 15, 598-611
40. Mitchell, D., Rodgers, K., Hanly, J., McMahon, B., Brady, H. R., Martin, F., and Godson, C. (2004) Lipoxins inhibit Akt/PKB activation and cell cycle progression in human mesangial cells. Am. J. Pathol. 164, 937-946 (Pubitemid 38235475)
41. Mitchell, D., O'Meara, S. J., Gaffney, A., Crean, J. K., Kinsella, B. T., and Godson, C. (2007) The Lipoxin A4 receptor is coupled to SHP-2 activation: implications for regulation of receptor tyrosine kinases. J. Biol. Chem. 282, 15606-15618 (Pubitemid 47093301)
42. Brezinski, D. A., Nesto, R. W., and Serhan, C. N. (1992) Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 86, 56-63
43. Pouliot, M., Clish, C. B., Petasis, N. A., Van Dyke, T. E., and Serhan, C. N. (2000) Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 39, 4761-4768
44. Bonnans, C., Vachier, I., Chavis, C., Godard, P., Bousquet, J., and Chanez, P. (2002) Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am. J. Respir. Crit. Care Med. 165, 1531-1535 (Pubitemid 34606669)
45. Planaguma, A., Kazani, S., Marigowda, G., Haworth, O., Mariani, T. J., Israel, E., Bleecker, E. R., Curran-Everett, D., Erzurum, S. C., Calhoun, W. J., Castro, M., Chung, K. F., Gaston, B., Jarjour, N. N., Busse, W. W., Wenzel, S. E., and Levy, B. D. (2008) Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am. J. Respir. Crit. Care Med. 178, 574-582
46. Karp, C. L., Flick, L. M., Park, K. W., Softic, S., Greer, T. M., Keledjian, R., Yang, R., Uddin, J., Guggino, W. B., Atabani, S. F., Belkaid, Y., Xu, Y., Whitsett, J. A., Accurso, F. J., Wills-Karp, M., and Petasis, N. A. (2004) Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5, 388-392
47. Wittamer, V., Gregoire, F., Robberecht, P., Vassart, G., Communi, D., and Parmentier, M. (2004) The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. J. Biol. Chem. 279, 9956-9962 (Pubitemid 38372597)
48. Yokomizo, T., Kato, K., Terawaki, K., Izumi, T., and Shimizu, T. (2000) A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 192, 421-432
49. Zabel, B. A., Nakae, S., Zuniga, L., Kim, J. Y., Ohyama, T., Alt, C., Pan, J., Suto, H., Soler, D., Allen, S. J., Handel, T. M., Song, C. H., Galli, S. J., and Butcher, E. C. (2008) Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J. Exp. Med. 205, 2207-2220
50. Barnea, G., Strapps, W., Herrada, G., Berman, Y., Ong, J., Kloss, B., Axel, R., and Lee, K. J. (2008) The genetic design of signaling cascades to record receptor activation. Proc. Natl. Acad. Sci. U. S. A. 105, 64-69
51. Funk, C. D. (2005) Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat. Rev. Drug Discov. 4, 664-672
52. Qiu, H., Gabrielsen, A., Agardh, H. E., Wan, M., Wetterholm, A., Wong, C. H., Hedin, U., Swedenborg, J., Hansson, G. K., Samuelsson, B., Paulsson-Berne, G., and Haeggstrom, J. Z. (2006) Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc. Natl. Acad. Sci. U. S. A. 103, 8161-8166
53. Edfeldt, K., Agerberth, B., Rottenberg, M. E., Gudmundsson, G. H., Wang, X. B., Mandal, K., Xu, Q., and Yan, Z. Q. (2006) Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 1551-1557
54. Hawthorne, A. B., Boughton-Smith, N. K., Whittle, B. J., and Hawkey, C. J. (1992) Colorectal leukotriene B4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5-lipoxygenase inhibitor BWA4C. Gut 33, 513-517
55. Schauber, J., Rieger, D., Weiler, F., Wehkamp, J., Eck, M., Fellermann, K., Scheppach, W., Gallo, R. L., and Stange, E. F. (2006) Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 18, 615-621